PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

Phase 2

Completed

Conditions: Fibromyalgia

Interventions: Drug: Esreboxetine

First Posted Date: 2008-09-15

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 89

Registration Number: NCT00752505

Locations: 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Drug: bisphosphonates, calcium, and vitamin D

First Posted Date: 2008-09-15

Last Posted Date: 2020-03-20

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT00752557

Locations: 🇺🇸
Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States
🇺🇸
Victoria Park Imaging, DeLand, Florida, United States
🇺🇸
Suncoast Clinical Research Inc, New Port Richey, Florida, United States

and more 31 locations

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Biological: ACC-001
Other: PBS
Other: QS-21

First Posted Date: 2008-09-15

Last Posted Date: 2016-01-01

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT00752232

Locations: 🇯🇵
Kitasato University East Hospital, Kanagawa, Japan
🇯🇵
Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan
🇯🇵
Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan

and more 7 locations

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALO-01
Drug: MSIR
Drug: Placebo

First Posted Date: 2008-09-12

Last Posted Date: 2013-09-16

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00751478

Locations: 🇨🇦
DecisionLine Clinical Research, Toronto, Ontario, Canada

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: timolol
Drug: PhXA41

First Posted Date: 2008-09-11

Last Posted Date: 2011-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 268

Registration Number: NCT00751127

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Drug: varenicline
Drug: placebo

First Posted Date: 2008-09-10

Last Posted Date: 2010-08-31

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT00749944

Locations: 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States

A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia

Phase 2

Withdrawn

Conditions: Insomnia

Interventions: Drug: Placebo
Drug: PD 0200390

First Posted Date: 2008-09-08

Last Posted Date: 2009-02-12

Lead Sponsor: Pfizer

Registration Number: NCT00748592

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: Tolterodine & Pregabalin
Drug: Placebo
Drug: Tolterodine
Drug: Pregabalin

First Posted Date: 2008-09-04

Last Posted Date: 2009-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 188

Registration Number: NCT00746681

Locations: 🇬🇧
Pfizer Investigational Site, Plymouth, United Kingdom

A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects

Phase 1

Completed

Conditions: Pain

Interventions: Drug: PF-3864086
Drug: Placebo

First Posted Date: 2008-09-04

Last Posted Date: 2010-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT00747058

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Varenicline
Drug: Placebo

First Posted Date: 2008-09-01

Last Posted Date: 2011-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00744978

Locations: 🇰🇷
Pfizer Investigational Site, Suwon, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy